Development and validation of a prognostic prediction model for alpha-fetoprotein-negative hepatocellular carcinoma with microvascular invasion after surgery

Figure 5 Subgroup analyses of survival based on clinical characteristics in the training cohort. The TGN score demonstrated excellent discriminative performance across all subgroups. A: Single tumor [log-rank, overall survival (OS): P < 0.001, disease-free survival (DFS): P = 0.001]; B: Multiple tumors (log-rank, OS: P < 0.001, DFS: P < 0.001); C: Barcelona Clinic Liver Cancer stage (0-A) (log-rank, OS: P < 0.001, DFS: P < 0.001); D: Barcelona Clinic Liver Cancer stage (B-C) (log-rank, OS: P < 0.001, DFS: P = 0.001); E: Without early recurrence (log-rank, OS: P < 0.001, DFS: P < 0.001); F: Early recurrence (log-rank, OS: P < 0.001, DFS: P < 0.001). TN: Tumor number; OS: Overall survival; DFS: Disease-free survival; BCLC: Barcelona Clinic Liver Cancer.